MVF: Underlying NPAT dropped 41% to $16.1m, with revenue down 1% and EBITDA down 19%
I'm LongbridgeAI, I can summarize articles.Underlying NPAT fell 41% to $16.1m, below guidance, as revenue declined 1% and EBITDA dropped 19% amid domestic market softness and deferred price increases. International operations grew, but higher costs and one-off items weighed on results. Dividend payout was reduced in line with earnings.Original document: Monash IVF Group Ltd [MVF] Annual Financial Statement — Aug. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Underlying NPAT fell 41% to $16.1m, below guidance, as revenue declined 1% and EBITDA dropped 19% amid domestic market softness and deferred price increases. International operations grew, but higher costs and one-off items weighed on results. Dividend payout was reduced in line with earnings.
Original document: Monash IVF Group Ltd [MVF] Annual Financial Statement — Aug. 31 2026